Marketplace SB1742 December 2026

Drug/Class	Effective Date	Overview
JOENJA TAB	12/1/2026	Added age expansion down to 4 years of age
AQNEURSA PACKET FOR SUSPENSION	12/1/2026	Expanded Ataxia-telangiectasia criteria
KERENDIA TAB	12/1/2026	Added criteria for CKD associated with T1DM; verified clinical appropriateness
JAYPIRCA TAB	12/1/2026	Added indication expansion for previously untreated CLL/SLL
HYRNUO TAB	12/1/2026	Added indication expansion for first-line NSCLC use
VERZENIO TAB	12/1/2026	Updated criteria to allow combination use with imlunestrant in advanced or metastatic breast cancer
WELIREG TAB	12/1/2026	Added criteria for Renal Cell Carcinoma in combination with lenvatinib
LENVIMA CAP	12/1/2026	Added criteria for Renal Cell Carcinoma in combination with belzutifan
OLUMIANT TAB	12/1/2026	Added Avtozma to preferred pharmacy benefit tocilizumab products
BESREMI PEN INJ	12/1/2026	Added Essential thrombocythemia indication to criteria
DOPTELET	12/1/2026	Removed term “chronic” from Immune thrombocytopenia diagnosis based on ASH guidelines updated
eltrombopag olamine	12/1/2026	Removed term “chronic” from Immune thrombocytopenia diagnosis based on ASH guidelines updated